Triple Negative Breast Cancer Clinical Trials in Columbus, Ohio

6 studies are recruiting for triple negative breast cancer in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

   The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabin…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ohio State University CRS, Columbus, Ohio

   Locations

   372 in total

   Run by

   Gilead Sciences

   See if you can join NCT05633654 on ClinicalTrials.gov

2. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

   This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus, Ohio

   Locations

   66 in total

   Run by

   Genmab

   See if you can join NCT05579366 on ClinicalTrials.gov

3. A Study of LY4175408 in Participants With Advanced Cancer

   The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Ohio State University (OSU) Wexner Medical Center, Columbus, Ohio

   Locations

   27 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07046923 on ClinicalTrials.gov

4. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

   This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Medical Center, Columbus, Ohio

   Locations

   15 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04468061 on ClinicalTrials.gov

5. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

   A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University, Columbus, Ohio

   Locations

   16 in total

   Run by

   OncoNano Medicine, Inc.

   See if you can join NCT06022029 on ClinicalTrials.gov

6. A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

   The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Ohio State University, Columbus, Ohio

   Locations

   10 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT06682793 on ClinicalTrials.gov